Literature DB >> 15003864

The impact of early immune destruction on the kinetics of postacute viral replication in rhesus monkey infected with the simian-human immunodeficiency virus 89.6P.

Zhi-Qiang Zhang1, William A Schleif, Danilo R Casimiro, Larry Handt, Minchun Chen, Mary-Ellen Davies, Xiaoping Liang, Tong-Ming Fu, Aimin Tang, Keith A Wilson, Michael McElhaugh, Anthony Carella, Charles Tan, Brett Connolly, Susan Hill, Hilton Klein, Emilio A Emini, John W Shiver.   

Abstract

Set-point viral load is positively correlated with the extent of initial viral replication in pathogenic simian-human immunodeficiency virus (SHIV) infection. To elucidate the mechanisms underlying the correlation, we conducted a systematic investigation in rhesus monkeys infected with the highly pathogenic SHIV 89.6P. This model is widely used in the preclinical evaluation of AIDS vaccine candidates and a thorough understanding of the model's biology is important to the proper interpretation of these evaluations. We found that the levels of peak viremia were positively correlated not only with the levels of set-point viremia but, importantly, with the extent of initial overall immune destruction as indicated by the degree of CD4+ T cell depletion and lymph node germinal center (GC) formation. The extent of initial overall immune destruction was inversely correlated with subsequent development and maintenance of virus-specific cellular and humoral immune responses. Thus, these data suggest that the extent of early immune damage determines the development and durability of virus-specific immunity, thereby playing a critical role in establishing the levels of set-point viral replication in SHIV infection. Vaccines that limit both the initial viral replication and the extent of early immune damage will therefore mediate long-term virus replication control and mitigation of long-term immune destruction in this model of immunodeficiency virus infection.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15003864     DOI: 10.1016/j.virol.2003.11.017

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  4 in total

1.  CCL3L1-CCR5 genotype influences durability of immune recovery during antiretroviral therapy of HIV-1-infected individuals.

Authors:  Sunil K Ahuja; Hemant Kulkarni; Gabriel Catano; Brian K Agan; Jose F Camargo; Weijing He; Robert J O'Connell; Vincent C Marconi; Judith Delmar; Joseph Eron; Robert A Clark; Simon Frost; Jeffrey Martin; Seema S Ahuja; Steven G Deeks; Susan Little; Douglas Richman; Frederick M Hecht; Matthew J Dolan
Journal:  Nat Med       Date:  2008-03-30       Impact factor: 53.440

2.  Simian-human immunodeficiency infection--is the course set in the acute phase?

Authors:  Janka Petravic; Miles P Davenport
Journal:  PLoS One       Date:  2011-02-17       Impact factor: 3.240

3.  Role of complement and antibodies in controlling infection with pathogenic simian immunodeficiency virus (SIV) in macaques vaccinated with replication-deficient viral vectors.

Authors:  Barbara Falkensammer; Barbara Rubner; Alexander Hiltgartner; Doris Wilflingseder; Christiane Stahl Hennig; Seraphin Kuate; Klaus Uberla; Stephen Norley; Alexander Strasak; Paul Racz; Heribert Stoiber
Journal:  Retrovirology       Date:  2009-06-21       Impact factor: 4.602

4.  CCL3L1-CCR5 genotype improves the assessment of AIDS Risk in HIV-1-infected individuals.

Authors:  Hemant Kulkarni; Brian K Agan; Vincent C Marconi; Robert J O'Connell; Jose F Camargo; Weijing He; Judith Delmar; Kenneth R Phelps; George Crawford; Robert A Clark; Matthew J Dolan; Sunil K Ahuja
Journal:  PLoS One       Date:  2008-09-08       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.